Login / Signup
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
Send us Feedback
BioCryst Pharmaceuticals (BCRX)
SUMMARY
BULLS
BEARS
DATA CENTRAL
STOCK CHART
BALANCE SHEET
INCOME STMT
CASH FLOW
Key Metrics for BCRX as compared to
Top Competitors
Biotechnology
Pharma & Healthcare
All values TTM unless otherwise noted (*)
INDUSTRY METRICS
No data.
Revenue
Net Income
Operating Income
INCOME STATEMENT (
See all
)
Revenue
►
53.9M
AVG
EBITDA
►
-16.9M
AVG
Net Income
►
-18.5M
AVG
Revenue Growth
►
6.8%
AVG
Operating Margin
►
-34.4%
AVG
Net Margin
►
-34.4%
AVG
Revenue, Net Income, and Net Margin
Revenue, Gross Profit, and Gross Margin
Operating Income
Ebit
Income Before Taxes
Net Income from Continuing Ops
Interest vs Continuing Income
Interest Coverage
Operating Expenses
Research & Development
SG&A
Amortization & Depreciation
BALANCE SHEET (most recent quarter) (
See all
)
Debt / Equity
►
1.57
AVG
Current Ratio
►
2.86
AVG
Quick Ratio
►
2.86
AVG
Book Value Per Share
►
0.626
Cash Per Share
►
0.485
Loading...
STOCK SUMMARY
Open
8.16
Day Range
8.14
-
8.41
52 Week Range
1.06
-
13.47
Volume
1.90M
Avg Volume (3 mo)
2.80M
Shares Outstanding
39.1M
Market Cap
317M
VALUATION
Price to Earnings (P/E)
►
-24.7
Price to Book (P/B)
►
19.4
HIGH
Price to Sales (P/S)
►
8.49
AVG
Return on Assets (ROA)
►
-23.2%
AVG
Return on Equity (ROE)
►
-63.3%
AVG
EV/EBITDA
►
-28.2
Dividend Yield
0%
AVG
ANALYST RECOMMENDATIONS
OWNERSHIP
Net Insider Buying 3mo
-4.6%
Net Insider Buying 6mo
-4.6%
Net Insider Buying 1yr
-11%
Held by insiders
26.1%
Held by institutions
32.5%
No Sales Breakout Data.